VENBIO PARTNERS LLC
Q4 2021 Form 13-F

SAN FRANCISCO, CALIFORNIA
CIK 0001776382 · CRD 290045 · Exempt reporting adviser
$555.1M Reported Value Total
Exempt Reporting Adviser
Source: Form ADV filed 2026-03-12
Reported value
$555.1M
Quarter over quarter
-52.7%
Holdings
9
Top-10 concentration
100.0%

Key People

Named on the latest Form 13-F filing — not necessarily an owner
David Pezeshki
Chief Financial Officer

Filing Navigation

13F Metrics

Loading 13F Metrics

Q4 2021 13F record

Q4 2021 13F filing summary

Q4 2021 Form 13F portfolio summary
Period of report December 31, 2021
Filed February 14, 2022
Form 13F-HR
Reported value $555.1M
Positions 9
Change in reported value -44.7%
New positions 1
Exited positions 1
Position turnover 20.0%
Top-10 concentration 100.0%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
9 $495.9M
Q2 2026 13F
Filed Aug 14, 2026
7 $519.4M
Q1 2026 13F
Filed May 15, 2026
6 $280.6M
Q4 2025 13F
Filed Feb 17, 2026
6 $216.3M
Q3 2025 13F
Filed Nov 14, 2025
6 $176.4M
Q2 2025 13F
Filed Aug 14, 2025
6 $114.8M
Q1 2025 13F
Filed May 15, 2025
7 $123.6M
Q4 2024 13F
Filed Feb 14, 2025
7 $170.7M
Q3 2024 13F
Filed Nov 14, 2024
6 $194.3M
Q2 2024 13F
Filed Aug 14, 2024
6 $231.5M
Q1 2024 13F
Filed May 15, 2024
5 $281.9M
Q4 2023 13F
Filed Feb 14, 2024
7 $667.2M
Q3 2023 13F
Filed Nov 14, 2023
8 $352.7M
Q2 2023 13F
Filed Aug 14, 2023
7 $276.3M
Q1 2023 13F
Filed May 15, 2023
6 $180.4M
Q4 2022 13F
Filed Feb 14, 2023
7 $322.5M
Q3 2022 13F
Filed Nov 14, 2022
8 $432.2M
Q2 2022 13F
Filed Aug 15, 2022
9 $351.2M
Q1 2022 13F
Filed May 16, 2022
10 $451.1M
Q4 2021 13F
Filed Feb 14, 2022
9 $555.1M

12 earlier quarters on file — choose one from the quarter menu above.

Top 9 holdings · Q4 2021

Largest Q4 2021 13F positions by reported value
# Holding Reported value % of portfolio
1 ALXO ALX ONCOLOGY HLDGS INC $208.5M 37.55%
2 HRMY HARMONY BIOSCIENCES HLDGS IN $116.9M 21.05%
3 VTYX VENTYX BIOSCIENCES INC $99.5M 17.93%
4 AKRO AKERO THERAPEUTICS INC $45.9M 8.28%
5 PHVS PHARVARIS N V $33.1M 5.97%
6 IMPL IMPEL NEUROPHARMA INC $23.8M 4.29%
7 ELEV ELEVATION ONCOLOGY INC $15.7M 2.83%
8 CMPI CHECKMATE PHARMACEUTICALS IN $10.5M 1.9%
9 VRNA VERONA PHARMA PLC $1.1M 0.2%

Values as reported on the Q4 2021 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings